Cyclosporin A inhibits hypoxia-induced pulmonary hypertension and right ventricle hypertrophy

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 6, 2006, Pages 699-705

  Koulmann, Nathalie ^a   Novel Chaté, Valérie ^b   Peinnequin, André ^b   Chapot, Rachel ^b   Serrurier, Bernard ^b   Simler, Nadine ^b   Richard, Hélène ^b   Ventura Clapier, Renée ^b   Bigard, Xavier ^b  

^a CENTRE DE RECHERCHES   (France)

^b NONE

Author keywords

Pulmonary hypertension; Right ventricle hypertrophy; Signal transduction

Indexed keywords

CYCLOSPORIN A; HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; MODULATORY CALCINEURIN INTERACTING PROTEIN 1; PROTEIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; GENE TARGETING; GENETIC CODE; GENETIC TRANSCRIPTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HEMATOCRIT; HYPOXIA; IN VIVO STUDY; MEDICAL ASSESSMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RAT; SEROTONIN BLOOD LEVEL; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION;

ANIMALS; ANOXIA; CALCINEURIN; CYCLOSPORINE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FOLLOW-UP STUDIES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG; MYOCARDIUM; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 33748703089     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200512-1976OC     Document Type: Article

References (43)

1. Newman JH. Pulmonary hypertension. Am J Respir Crit Care Med 2005;172:1072-1077.
2. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S.
3. MacLean MR, Hervé P, Eddahibi S, Adnot S. 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters, and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000;131:161-168.
4. Eddahibi S, Fabre V, Boni C, Martres MP, Raffestin B, Hamon M, Adnot S. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells: relationship with the mitogenic action of serotonin. Circ Res 1999;84:329-336.
5. Eddahibi S, Adnot S, Frisdal E, Levame M, Hamon M, Raffestin B. Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J Pharmacol Exp Ther 2001;297:148-154.
6. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 2000;105:1555-1562.
7. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen S, Sheward J, Colston J, Loughlin L, Nilsen M, Dempsie Y, et al. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 2004;109:2150-2155.
8. Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002;8:1129-1135.
9. Liu Y, Suzuki YJ, Day RM, Fanburg BL. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 2004;95:579-586.
10. 2A receptor and transporter. Am J Respir Crit Care Med 2004;170:252-259.
11. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty R, Sham JSK, Wiener CM, Sylvester JT, et al. Impaired physiologic responses to chronic hypoxia in mice partially deficient for hypoxiainducible factor 1α. J Clin Invest 1999;103:691-696.
12. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-1480.
13. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004;19:176-182.
14. Semenza GL,Wang GL. Anuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447-5454.
15. Shimoda LA, Manalo DJ, Sham JSK, Semenza GL, Sylvester JT. Partial HIF-1α deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am J Physiol Lung Cell Mol Physiol 2001;281:L202-L208.
16. 2 tension. Proc Natl Acad Sci USA 1995;92:5510-5514.
17. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 2002;111:709-720.
18. Semenza GL. Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. Chest 2005;128:592S-594S.
19. D'Angelo G, Duplan E, Vigne P, Frelin C. Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1α Pro-564 hydroxylation. J Biol Chem 2003;278:15406-15411.
20. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 2004;322:1178-1191.
21. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Planck DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004;94:110-118.
22. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert C, Gualberto A, Wieczorek DF, Molkentin JD. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998;281:1690-1693.
23. Koulmann N, Sanchez H, Letout A, Ventura-Clapier R, Bigard AX. Role of calcineurin in chronic hypoxia-induced hypertrophic response of right ventricle. Presented at the Third Meeting of Heart Failure and Annual Congress of the European Section of the International Society for Heart Research, Strasbourg, France, June 21-24, 2003. Abstract 316 published in Eur J Heart Fail 2003;2:57.
24. Koulmann N. Sanchez H, Letout A, Ventura-Clapier R, Bigard AX. Role of calcineurin in chronic hypoxia-induced hypertrophic response of right ventricle. Presented at the Third Federation of European Physiological Societies Congress, Nice, France, June 28-July 2, 2003.
25. Koulmann N, Novel-Chaté V, Peinnequin A, Chapot R, Serrurier B, Richard H, Ventura-Clapier R, Bigard X. Cyclosporin A prevents hypoxia-induced responses by inhibiting both calcineurin pathway and HIF-1 transcriptional activity. Presented at Experimental Biology 2005, San Diego, CA, April 2-6, 2005.
26. Goldspink PH, McKinney RD, Kimball VA, Geenen DL, Buttrick PM. Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats. Mol Cell Biochem 2001;226:83-88.
27. Murat A, Pellieux C, Brunner HR, Pedrazzini ET. Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. J Biol Chem 2000;275:40867-40873.
28. T) method. Methods 2001;25:402-408.
29. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:Research 0034.1-0034.11.
30. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olson EN, Bassel-Duby R, Williams RS. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res 2000;87:E61-E68.
31. Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev 2000;80:1483-1521.
32. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81.
33. Welsh DJ, Scott P, Plevin R, Wadsworth R, Peacock AJ. Hypoxia enhances cellular proliferation and inositol 1,4,5-triphosphate generation in fibroblasts from bovine pulmonary artery but not from mesenteric artery. Am J Respir Crit Care Med 1998;158:1757-1762.
34. Bush E, Fielitz J, Melvin L, Martinez-Arnold M, McKinsey TA, Plichta R, Olson EN. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signalling pathway. Proc Natl Acad Sci USA 2004;101:2870-2875.
35. 2+ and nonselective cation channels. Am J Physiol Lung Cell Mol Physiol 2005;289:5-13.
36. Yellaturu CR, Ghosh SK, Rao RK, Jennings LK, Hassid A, Rao GN. A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced cell proliferation. Biochem J 2002;368:183-190.
37. Bengel D, Heils A, Petri S, Seemann M, Glatz K, Andrews A, Murphy DL, Lesch KP. Gene structure and 5′-flanking regulatory region of the murine serotonin transporter. Brain Res Mol Brain Res 1997;44:286-292.
38. Lukashev D, Caldwell C, Ohta A, Chen P, Sitkovsy M. Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1α in activated T lymphocytes. J Biol Chem 2001;276:48754-48763.
39. Banchero N. Cardiovascular responses to chronic hypoxia. Annu Rev Physiol 1987;49:465-476.
40. Wilkins BJ, Molkentin JD. Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol 2002;541:1-8.
41. McLaughin V, Hoeper MM. Pulmonary arterial hypertension: the race for the most effective treatment. Am J Respir Crit Care Med 2005;171:1199-1201.
42. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, Oka M. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171:494-499.
43. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 2005;171:1292-1297.